 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LCAR-AIO / Legend Biotech
New P1 trial: A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases (clinicaltrials.gov) - Mar 11, 2025
P1, N=37, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- || LCAR-AIO / Legend Biotech
Enrollment open: A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - Jan 10, 2025
P1, N=34, Recruiting, Sponsor: Wuhan Union Hospital, China
Not yet recruiting --> Recruiting
- || LCAR-AIO / Legend Biotech
New P1 trial: A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 22, 2024
P1, N=34, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
- || LCAR-AIO / Legend Biotech
Enrollment closed, Enrollment change: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov) - May 14, 2024
P1, N=20, Active, not recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=34 --> 20
- || LCAR-AIO / Legend Biotech
Enrollment open: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov) - Apr 21, 2022
P1, N=34, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital
Recruiting --> Active, not recruiting | N=34 --> 20 Not yet recruiting --> Recruiting
- || LCAR-AIO / Legend Biotech
New P1 trial: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov) - Apr 8, 2022
P1, N=34, Recruiting, Sponsor: Qiu Lugui
- || LCAR-AIO / Legend Biotech
New P1 trial: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (clinicaltrials.gov) - Mar 22, 2022
P1, N=34, Not yet recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital
- LCAR-AIO / Legend Biotech
Tri-Specific CD19xCD20xCD22 VHH CAR-T Cells (LCAR-AIO) Eradicate Antigen-Heterogeneous B Cell Tumors, Enhance Expansion, and Prolong Persistence in Preclinical In Vivo Models (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3283;
Based on in vitro and in vivo preclinical data, tri-specific CD19xCD20xCD22 VHH CAR-T can be effective targeting tumors lack of CD19 expression, therefore, it has the potential of treating relapsed patients with prior CD19 CAR-T therapy. The feasibility of making tri-specific CAR-T would help to extend this technology to solid cancers where heterogeneity poses a major challenge at current stage.